Cancer is a heterogeneous disease, meaning every tumour may addict to distinct oncogenic mechanisms and therefore need personalised treatment. This complexity could arise from genomic alterations (e.g. mutations), microenvironment changes (e.g. immune cells) and their interactions. Nevertheless, current therapeutic development mainly focuses on one of these alterations, resulting poor response in many cases.
Dr Haonan Lu was previously trained in bioinformatics and cell biology at Imperial College London. He is particularly interested in developing imaging-based methods to describe cancer phenotypes, as well as discovering novel therapeutic targets through functional genomics approach.
et al., 2021, Discovery of a biomarker candidate for surgical stratification in high-grade serous ovarian cancer, British Journal of Cancer, Vol:124, ISSN:0007-0920, Pages:1286-1293
et al., 2021, Endogenous aldehyde accumulation generates genotoxicity and exhaled biomarkers in esophageal adenocarcinoma., Nat Commun, Vol:12
et al., 2021, The Oxford Classic links epithelial-to-mesenchymal transition to immunosuppression in poor prognosis ovarian cancers, Clinical Cancer Research, Vol:27, ISSN:1078-0432, Pages:1570-1579
et al., 2021, Transcriptional analysis of multiple ovarian cancer cohorts reveals prognostic and immunomodulatory consequences of ERV expression, Journal for Immunotherapy of Cancer, Vol:9, ISSN:2051-1426
et al., 2020, Monitoring response to transarterial chemoembolization in hepatocellular carcinoma using 18F-Fluorothymidine Positron Emission Tomography, The Journal of Nuclear Medicine, Vol:61, ISSN:0161-5505, Pages:1743-1748